In This Section

Recent Press Releases

June 1, 2018

Europe represents potentially the largest market for metreleptin with expected authorization in both generalized and partial lipodystrophy

May 10, 2018

VANCOUVER, B.C., May 10, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases ("Novelion" or the "Company"), today reported financial results for the first quarter ended March 31, 2018 and provided an overview of business activities.

March 15, 2018

Aegerion strengthens balance sheet and liquidity, positioning company for ongoing capital structure review